Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 1999

View Archived Issues

Bavarian Nordic's tyrosinase vector enters safety study in Germany

Genset and Algene enter strategic alliance for AD research

Hollis-Eden and U.S. Naval Medical Center collaborate on malaria research

Aradigm and Genentech sign development agreement for cystic fibrosis therapy

Suplatast tosilate, a novel mediator release inhibitor with potential in the treatment of IC

Company Profile: QIK Technology

Interferon Sciences announces results of FDA prefiling conference

Company Profile: Synt:em

Resiniferatoxin improves symptoms of overactive bladder in preclinical, clinical studies

Cell Therapeutics terminates enrollment in lung injury trial of lisofylline

FDA approves Enbrel for JRA

Dainippon establishes Korean partnership for mosapride citrate

Licensing opportunity from Fox Chase Cancer Center: MDR-reversing agents

Lundbeck and Cephalon sign neurological R&D agreement

Cerebrus licenses AD drug from SmithKline Beecham

Another series of naphthosultam-substituted carbapenems in development at Merck

Merck presents new class of potassium channel blockers and immunosuppressants

Orally active anticoagulants described by Daiichi

Opioid analgesics related to enkephalin prepared at Suntory

Mitsubishi Chemical group describes inhibitors of EGF TK and tumor cell proliferation

PGI2 agonists under study at Fujisawa

FDA gives green light for Core's pivotal studies on metronidazole Hycore-V

Investigators uncover basis for ocular side effects of sildenafil

Spray formulation of isosorbide dinitrate superior to tablet formulation in hypertensive emergencies

New treatment strategy for BPH: CRM197 inhibits bladder smooth muscle cell proliferation

DHA and EPA have differential effects on ambulatory BP and HR in humans

DuPont's once-daily HIV drug approved in Europe

Orlistat as adjunct to hypocaloric diet reduces CVD risk factors in obesity

AstraZeneca celebrates first day of operations as a unified business

Novel treatment for calcium oxalate stones presented at AUA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...